Apothékary Lands $16M To Fuel Retail Growth And Product Innovation Herbal tinctures brand Apothékary has raised $16 million in fresh funding to expand retail distribution and accelerate product innovation. Read More from the Global Wellness News ™
Real estate pivots to longevity residences
Real estate pivots to longevity residences Luxury “longevity residences” are real estate’s next big thing, capitalizing on growing demand for wellness at any age. Read More from the Global Wellness News ™
Gyms Build Around GLP-1s
Gyms Build Around GLP-1s Fitness operators are positioning themselves as the missing layer between weight-loss drugs and long-term health. Read More from the Global Wellness News ™
For the First Time, These Wellness Resorts Are Opening Up to Kids and Tweens
For the First Time, These Wellness Resorts Are Opening Up to Kids and Tweens Even infants can get in on the action. Read More from the Global Wellness News ™
Xella Health Launches Multi-Omic Diagnostics Platform for Women’s Care
Xella Health Launches Multi-Omic Diagnostics Platform for Women’s Care Aiming to “replace systemic medical gaslighting,” co-founder Kelly Lacob wants to make indisputable biological data the standard for care. Read More from the Global Wellness News ™
Peers Capital bets on prevention before the pivot
Peers Capital bets on prevention before the pivot New deal-by-deal syndicate is backing founders in diagnostics, longevity, recovery and behavior change – before traditional investors arrive. Read More from the Global Wellness News ™
Is this the era of ‘passive neuro-wearables’?
Nike’s ‘mind-altering’ shoes are flying off shelves. Is this the era of ‘passive neuro-wearables’? | CNN Nike’s Mind shoe range has rapidly sold out across worldwide releases with buyers eager to get their hands on the “neuroscience-based footwear.” Read More from the Global Wellness News ™
Silicon Valley’s longevity drug obsession is facing its first real reality check
Silicon Valley’s longevity drug obsession is facing its first real reality check Bryan Johnson, the tech entrepreneur who turned his body into a public experiment, stopped taking Rapamycin in September 2024 after several years of self-testing the drug. The… Read More from the Global Wellness News ™
New $500 Million Fund Is Trying to Eliminate the Common Cold
A New $500 Million Fund Is Trying to Eliminate the Common Cold The project, called Intercept, aims to financially back the development of treatments that protect against respiratory infections of all kinds, plus technology to clean air. Read More from the Global Wellness News ™
Unilever exploring $4 billion bid for Thorne supplements
Unilever exploring $4 billion bid for Thorne supplements L Catterton, the LVMH-backed private equity firm that took Thorne private for $680 million in 2023, is seeking a valuation of up to $4 billion Read More from the Global Wellness News ™